×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Marinus Pharmaceuticals Inc. (MRNS) NASDAQ

$8.93 0.08 (0.90%)

Market Cap: $483.59M

As of 03/28/24 10:38 AM EDT. Market open.

(MRNS)

Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ

$8.93
0.08 (0.90%)

Market Cap: $483.59M

As of 03/28/24 10:38 AM EDT. Market open.

Add to Portfolio

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced ... read more

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$520,000
CEO Compensation (Total)
$725,000
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
142
CEO Compensation (Base)
$520,000
CEO Compensation (Total)
$725,000
Address
.
PRICE CHART FOR MARINUS PHARMACEUTICALS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$8.99
Previous Close
$8.85
Days Range
$8.61 - $9.07
52 week range
$5.57 - $11.26
Volume
85,784
Avg. Volume (30 days)
545,512
Market Cap
$483.59M
Dividend Yield
-
P/E
(3.42)
Shares Outstanding
54,642,580
Open
$8.99
Previous Close
$8.85
Days Range
$8.61 - $9.07
52 week range
$5.57 - $11.26
Volume
85,784
Avg. Volume (30 days)
545,512
Market Cap
$483.59M
Dividend Yield
-
P/E
(3.42)
Shares Outstanding
54,642,580
FINANCIAL STATEMENTS FOR MARINUS PHARMACEUTICALS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR MARINUS PHARMACEUTICALS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Braunstein ScottCHAIRMAN AND CEOMar 27, 2024 Option Exercise$4.2850,000214,000273,512Mar 27, 2024, 11:55 AM
Shafer ChristinaCHIEF COMMERCIAL OFFICERFeb 20, 2024 Sale$9.562,15320,58360,308Feb 22, 2024, 04:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERFeb 16, 2024 Sale$9.982,81428,08466,635Feb 21, 2024, 04:06 PM
Braunstein ScottCHAIRMAN AND CEOFeb 16, 2024 Sale$9.9411,850117,789223,512Feb 21, 2024, 04:05 PM
Shafer ChristinaCHIEF COMMERCIAL OFFICERAug 07, 2023 Sale$9.522,38522,70540,637Aug 08, 2023, 09:05 PM
Shafer ChristinaCHIEF COMMERCIAL OFFICERAug 08, 2023 Sale$8.93119840,626Aug 08, 2023, 09:05 PM
Braunstein ScottCHAIRMAN AND CEOAug 08, 2023 Sale$8.9430268160,762Aug 08, 2023, 09:05 PM
Braunstein ScottCHAIRMAN AND CEOAug 07, 2023 Sale$9.556,41361,244160,792Aug 08, 2023, 09:05 PM
Pfanstiel StevenCFO AND COOAug 08, 2023 Sale$8.931412549,324Aug 08, 2023, 09:05 PM
Pfanstiel StevenCFO AND COOAug 07, 2023 Sale$9.542,79026,61749,338Aug 08, 2023, 09:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Aug 08, 2023 Sale$8.93119833,025Aug 08, 2023, 09:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Aug 07, 2023 Sale$9.542,16920,69233,036Aug 08, 2023, 09:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERAug 08, 2023 Sale$8.931311647,614Aug 08, 2023, 09:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERAug 07, 2023 Sale$9.552,88927,59047,627Aug 08, 2023, 09:05 PM
Fischer Seth H. Z.DirectorFeb 06, 2023 Sale$6.541,0186,6586,026Feb 08, 2023, 04:37 PM
Ezickson ElanDirectorFeb 06, 2023 Sale$6.567504,9205,600Feb 08, 2023, 04:36 PM
Austin CharlesDirectorFeb 06, 2023 Sale$6.491,0736,9645,277Feb 08, 2023, 04:36 PM
Shafer ChristinaChief Commercial OfficerNov 09, 2022 Option Exercise$4.701,5057,07325,647Nov 14, 2022, 07:43 AM
VITULLO NICOLEDirectorMar 15, 2021 Sale$15.874,25067,4470Mar 16, 2021, 04:58 PM
Smith Edward FFormer VP, CFO & TreasurerMar 09, 2021 Option Exercise$4.1635,927149,45653,644Mar 11, 2021, 04:04 PM
Smith Edward FFormer VP, CFO & TreasurerMar 09, 2021 Sale$17.8040,356718,33713,288Mar 11, 2021, 04:04 PM
Smith Edward FCFOJan 30, 2020 Sale$2.052,3804,87917,717Feb 03, 2020, 06:29 PM
Braunstein ScottChief Executive OfficerDec 13, 2019 Buy$1.25100,000125,000100,000Dec 13, 2019, 04:08 PM
Smith Edward FCFOMay 16, 2019 Sale$5.0324,211121,78120,097May 20, 2019, 04:20 PM
Cashman Christopher MichaelCEOMar 18, 2019 Option Exercise$1.0431,66232,928271,423Mar 20, 2019, 05:57 PM
Cashman Christopher MichaelCEOJan 28, 2019 Sale$3.138,14225,484239,761Jan 30, 2019, 04:09 PM
Smith Edward FCFOJan 29, 2019 Sale$3.062,4927,62644,308Jan 30, 2019, 04:08 PM
Smith Edward FCFOJan 29, 2018 Sale$7.913,00023,73049,800Jan 29, 2018, 08:00 PM
Cashman Christopher MichaelCEOJan 18, 2018 Sale$6.289,56660,074247,903Jan 22, 2018, 08:41 PM
Bain Capital Life Sciences Investors, LLC10% OwnerDec 15, 2017 Sale$8.10822,5476,658,6914,530,335Dec 19, 2017, 08:30 PM
Bain Capital Life Sciences Investors, LLC10% OwnerDec 19, 2017 Sale$7.43150,0001,114,6704,032,682Dec 19, 2017, 08:30 PM
Bain Capital Life Sciences Investors, LLC10% OwnerDec 18, 2017 Sale$7.50300,0002,251,4404,127,453Dec 19, 2017, 08:30 PM
Mehra Anand10% OwnerOct 20, 2016 Sale$1.39750,6831,042,6991,134,851Oct 24, 2016, 04:49 PM
Canaan VII LP10% OwnerAug 08, 2016 Sale$1.5019,95029,9251,850,783Aug 09, 2016, 10:03 AM
Canaan VII LP10% OwnerAug 05, 2016 Sale$1.50129,204193,8061,870,733Aug 09, 2016, 10:03 AM
Canaan VII LP10% OwnerAug 04, 2016 Sale$1.503,3294,9941,999,937Aug 05, 2016, 10:18 AM
Canaan VII LP10% OwnerAug 03, 2016 Sale$1.50142,254213,3812,003,266Aug 05, 2016, 10:18 AM
Canaan VII LP10% OwnerJul 29, 2016 Sale$1.7124,54041,9632,145,520Aug 02, 2016, 12:22 PM
Canaan VII LP10% OwnerJul 27, 2016 Sale$1.802093762,170,060Jul 27, 2016, 04:30 PM
Canaan VII LP10% OwnerJul 26, 2016 Sale$1.8120,38036,8882,170,269Jul 27, 2016, 04:30 PM
Canaan VII LP10% OwnerJul 25, 2016 Sale$1.86137,617255,9682,190,649Jul 26, 2016, 10:08 AM
Canaan VII LP10% OwnerJul 22, 2016 Sale$1.94133,133258,2782,328,266Jul 26, 2016, 10:08 AM
Cashman Christopher MichaelPresident and CEOFeb 09, 2016 Option Exercise$1.0424,68425,671140,769Feb 11, 2016, 05:17 PM
Cashman Christopher MichaelPresident and CEONov 06, 2015 Buy$5.613,56119,977116,085Feb 11, 2016, 05:17 PM
Bloch Stephen MDirectorSep 28, 2015 Option Exercise$1.0439,55041,13239,550Feb 04, 2016, 06:48 PM
Bloch Stephen MDirectorSep 28, 2015 Option Exercise$1.0439,55041,13239,550Sep 28, 2015, 08:12 PM
MAYLEBEN TIMOTHY MDirectorJul 16, 2015 Option Exercise$1.0442,55044,25242,550Jul 17, 2015, 04:01 PM
Cashman Christopher MichaelPresident and CEOJul 01, 2015 Option Exercise$1.0414,08614,649112,524Jul 02, 2015, 04:08 PM
Bloch Stephen MDirectorJun 10, 2015 Option Exercise$1.043,0003,1203,000Jun 11, 2015, 05:26 PM
Farfel Gail MChief Clinical Dev & Reg OfficApr 21, 2015 Option Exercise$1.0430,00031,20030,000Apr 23, 2015, 04:48 PM
Farfel Gail MChief Clinical Dev & Reg OfficApr 21, 2015 Sale$9.4830,000284,5110Apr 23, 2015, 04:48 PM
Cashman Christopher MichaelPRESIDENT AND CEOMar 06, 2015 Option Exercise$1.0417,60818,31298,438Mar 10, 2015, 01:16 PM
Cashman Christopher MichaelPRESIDENT AND CEOOct 08, 2014 Option Exercise$1.0480,83084,06380,830Oct 09, 2014, 04:05 PM
Domain Partners VI, L.P.10% OwnerAug 05, 2014 Buy$8.00419,7443,357,9522,476,886Aug 07, 2014, 03:06 PM
Mehra AnandDirectorAug 05, 2014 Buy$8.00750,6836,005,4641,859,639Aug 07, 2014, 12:43 PM
Canaan VII L PDirectorAug 05, 2014 Buy$8.00625,0005,000,0002,461,398Aug 06, 2014, 09:03 AM
Bloch Stephen MDirectorAug 05, 2014 Buy$8.00625,0005,000,0002,461,398Aug 06, 2014, 09:03 AM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Braunstein ScottCHAIRMAN AND CEO03/27/2024214,000
Shafer ChristinaCHIEF COMMERCIAL OFFICER02/20/202420,583
Hulihan JosephCHIEF MEDICAL OFFICER02/16/202428,084
Braunstein ScottCHAIRMAN AND CEO02/16/2024117,789
Shafer ChristinaCHIEF COMMERCIAL OFFICER08/07/202322,705
Shafer ChristinaCHIEF COMMERCIAL OFFICER08/08/202398
Braunstein ScottCHAIRMAN AND CEO08/08/2023268
Braunstein ScottCHAIRMAN AND CEO08/07/202361,244
Pfanstiel StevenCFO AND COO08/08/2023125
Pfanstiel StevenCFO AND COO08/07/202326,617
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.08/08/202398
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.08/07/202320,692
Hulihan JosephCHIEF MEDICAL OFFICER08/08/2023116
Hulihan JosephCHIEF MEDICAL OFFICER08/07/202327,590
Fischer Seth H. Z.Director02/06/20236,658
Ezickson ElanDirector02/06/20234,920
Austin CharlesDirector02/06/20236,964
Shafer ChristinaChief Commercial Officer11/09/20227,073
VITULLO NICOLEDirector03/15/202167,447
Smith Edward FFormer VP, CFO & Treasurer03/09/2021149,456
Smith Edward FFormer VP, CFO & Treasurer03/09/2021718,337
Smith Edward FCFO01/30/20204,879
Braunstein ScottChief Executive Officer12/13/2019125,000
Smith Edward FCFO05/16/2019121,781
Cashman Christopher MichaelCEO03/18/201932,928
Cashman Christopher MichaelCEO01/28/201925,484
Smith Edward FCFO01/29/20197,626
Smith Edward FCFO01/29/201823,730
Cashman Christopher MichaelCEO01/18/201860,074
Bain Capital Life Sciences Investors, LLC10% Owner12/15/20176,658,691
Bain Capital Life Sciences Investors, LLC10% Owner12/19/20171,114,670
Bain Capital Life Sciences Investors, LLC10% Owner12/18/20172,251,440
Mehra Anand10% Owner10/20/20161,042,699
Canaan VII LP10% Owner08/08/201629,925
Canaan VII LP10% Owner08/05/2016193,806
Canaan VII LP10% Owner08/04/20164,994
Canaan VII LP10% Owner08/03/2016213,381
Canaan VII LP10% Owner07/29/201641,963
Canaan VII LP10% Owner07/27/2016376
Canaan VII LP10% Owner07/26/201636,888
Canaan VII LP10% Owner07/25/2016255,968
Canaan VII LP10% Owner07/22/2016258,278
Cashman Christopher MichaelPresident and CEO02/09/201625,671
Cashman Christopher MichaelPresident and CEO11/06/201519,977
Bloch Stephen MDirector09/28/201541,132
Bloch Stephen MDirector09/28/201541,132
MAYLEBEN TIMOTHY MDirector07/16/201544,252
Cashman Christopher MichaelPresident and CEO07/01/201514,649
Bloch Stephen MDirector06/10/20153,120
Farfel Gail MChief Clinical Dev & Reg Offic04/21/201531,200
Farfel Gail MChief Clinical Dev & Reg Offic04/21/2015284,511
Cashman Christopher MichaelPRESIDENT AND CEO03/06/201518,312
Cashman Christopher MichaelPRESIDENT AND CEO10/08/201484,063
Domain Partners VI, L.P.10% Owner08/05/20143,357,952
Mehra AnandDirector08/05/20146,005,464
Canaan VII L PDirector08/05/20145,000,000
Bloch Stephen MDirector08/05/20145,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN MARINUS PHARMACEUTICALS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
SUVRETTA CAPITAL MANAGEMENT, LLC5,346,1192.63%2.71%Growth At A Reasonable Price
BLACKROCK INC.4,599,2780.00127%10.94%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.2,581,2500.06%-11.13%Other
GEODE CAPITAL MANAGEMENT, LLC1,139,4940.0013%9.05%Other
D. E. SHAW & CO., INC.50,000 (Call)0.00042%ExitedOther
AQR CAPITAL MANAGEMENT LLC23,0240.00047%NewOther
BALYASNY ASSET MANAGEMENT L.P.15,8730.00026%ExitedEvent Driven
D. E. SHAW & CO., INC.11,4000.0001%ExitedOther
CHANGE IN SHARES OUTSTANDING FOR MARINUS PHARMACEUTICALS INC
STOCK BUYBACKS FOR MARINUS PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
5.19%
1Q
12/31/2023
06/30/2023
7.93%
2Q
12/31/2023
03/31/2023
9.56%
3Q
12/31/2023
12/31/2022
37.98%
4Q
12/31/2023
09/30/2022
49.62%
5Q
12/31/2023
06/30/2022
52.66%
6Q
12/31/2023
03/31/2022
53.75%
7Q
12/31/2023
12/31/2021
54.19%
8Q
12/31/2023
09/30/2021
54.36%
9Q
12/31/2023
06/30/2021
54.72%
10Q
12/31/2023
03/31/2021
54.98%
11Q
12/31/2023
12/31/2020
78.00%
12Q
12/31/2023
09/30/2020
85.65%
13Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
5.19%
1Q
06/30/2023
7.93%
2Q
03/31/2023
9.56%
3Q
12/31/2022
37.98%
4Q
09/30/2022
49.62%
5Q
06/30/2022
52.66%
6Q
03/31/2022
53.75%
7Q
12/31/2021
54.19%
8Q
09/30/2021
54.36%
9Q
06/30/2021
54.72%
10Q
03/31/2021
54.98%
11Q
12/31/2020
78.00%
12Q
09/30/2020
85.65%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR MARINUS PHARMACEUTICALS INC
LOADING...